Kali-Extracts Announces Second $100,000 Hemp4mula Order For New CBD Infused Gummies
January 10 2019 - 11:21AM
InvestorsHub NewsWire
Kali-Extracts Announces Second $100,000 Hemp4mula
Order For New CBD Infused Gummies
Dallas, TX -- January 10, 2019 -- InvestorsHub
NewsWire -- Kali-Extracts, Inc. (Kali, Inc.
dba/Kali-Extracts, Inc.)
(KALY) ("KALY") today announced a $100,000
wholesale order of its new Hemp4mula CBD Infused
Gummies. The wholesale buyer
recently ordered
$100,000 of KALY's Hemp4mula CBD Infused Chewing Gum. The wholesale
buyer plans
to have both
the Hemp4mula CBD Infused Chewing
Gum and
Gummies available for sale at select
retail drugstore locations and through the soon to be launched USMJ
E-commerce Site from North
American Cannabis Holdings, Inc.
(USMJ).
In
December,
Kali-Extracts announced launching its own line of hemp-derived CBD
infused candies and vapes under the brand name Hemp4mula.
Kali-Extracts
Hemp4mula CBD Infused Chewing Gum will come in a blister back of 8
pieces with 10 mg each of hemp-derived CBD. Kali-Extracts Hemp4mula CBD
Infused Gummies will come in a container of 30 pieces with 10 mg
each of hemp-derived CBD. Kali-Extracts expects to
soon
produce
hemp-derived CBD infused mints in addition the chewing gum and
gummies.
Hemp4mula vapes are anticipated to also soon be in
production.
KALY recently acquired
a
biotech company
with a patented cannabis extraction process. Accordingly, KALY updated its
overall business plan (a presentation on the company's updated
business plan is available on KALY's website). Hemp4mula is part of the updated business
plan which management is rapidly executing. The company
recently
announced a
$300,000 hemp-derived CBD
extraction contract with Puration, Inc. (PURA).
The CBD Kali-extracts will
produce is to support PURA's contract to produce a private
labeled CBD infused Water for Generex Biotechnology, (GNBT).
Goldman Small Cap Research
Report published an analyst research report on KALY this past
Tuesday, January 8th, 2019 that highlights KALY's
cannabis pharmaceutical value. The report is available under
"research" on the OTCMarkets
website.
The research report is the first report from Goldman Small Cap
Research as part of an ongoing research engagement. The report
outlines the company's current positioning and potential, upcoming
milestones. The report is intended to augment the current
information available on the OTCMarkets website. The report is also
available to read or download, along with associated disclosures
and disclaimers, at www.GoldmanResearch.com.
To learn more about the company
visit https://www.kali-extracts.com/
Check back frequently to the
company's website and to the OTCMarkets website for more updates coming
soon as management populates the new company website with
additional information and brings all corporate information current
on the OTCMarkets website.
This press release contains
forward-looking statements within the meaning of Section 27A of the
Securities Act of 1933, as amended, and Section 21E of the
Securities Exchange Act of 1934, as amended (the "Exchange Act"),
and as such, may involve risks and uncertainties. These forward
looking statements relate to, amongst other things, current
expectation of the business environment in which the company
operates, potential future performance, projections of future
performance and the perceived opportunities in the market. The
company's actual performance, results and achievements may differ
materially from the expressed or implied in such forward-looking
statements as a result of a wide range of factors.
CONTACT:
Frederick
Ferri
ir@kali-extracts.com
(214) 210-0459
Kali (CE) (USOTC:KALY)
Historical Stock Chart
From Aug 2024 to Sep 2024
Kali (CE) (USOTC:KALY)
Historical Stock Chart
From Sep 2023 to Sep 2024